Molecular Testing for Breast Cancer

Autor: OncoLink Team
Última Vez Revisión: 15 de octubre de 2018

When breast cancer is diagnosed, the tumor tissue is tested for several "biomarkers". These markers are substances or abnormalities that can be detected in the tumor tissue and used to predict prognosis and guide treatment recommendations. This may be referred to as "personalized medicine". These tests allow your treatment team to choose the right treatment for your tumor's characteristics.

Molecular testing for breast cancer includes:

  • Hormone receptor status:
    • This test reports if the tumor has an excess of estrogen and/or progesterone receptors. You may have one or both receptors positive. A positive result is called ER+/PR+, though how the result is reported varies depending on the test. Results may be reported as:
      • A percentage of the cells that reacted positive for receptors (from 0% to 100%).
      • A number between 0 and 3, with 0 being no receptors and 3 being the most receptors.
      • An Allred score is a combination of the percent positive and their intensity. The score is from 0-9, with 9 being the most strongly receptor positive.
      • Positive or negative.
    • ER+ and/or PR+ tumors may be treated with hormone therapy, which works by blocking the tumor cells from getting the estrogen and progesterone they need to grow.
  • HER2/neu Status:
    • HER2/neu stands for human epidermal growth factor receptor 2, which is a protein that is found on the surface of some patient's breast cancer cells.
    • The HER2/neu test result may be reported as positive or negative (FISH test) OR as a score between 0 and +3 (IHC test), depending on the type of test used.
    • If the IHC test is used, a score of 0 or +1 is considered HER2 negative. A score of +3 is HER2 positive. A score of +2 is unclear and should be sent for the FISH test to confirm the HER2 status.
    • Tumors that are HER2 positive may be treated with medications that specifically target this receptor.
  • OncoType Dx Test:
    • This test analyzes the activity of 21 genes found in the tumor cells and uses that information to predict the risk of recurrence (the risk of the cancer coming back after treatment), how likely a patient is to benefit from chemotherapy treatment after surgery in early stage cancer, or the benefit from receiving radiation therapy after DCIS surgery.
    • This test may be used for DCIS or stage I or II invasive breast cancers that are ER+ (estrogen receptor positive) and have no cancer spread to the lymph nodes.
    • The result is reported as a "Recurrence Score", which is a number from 0 to 100 that corresponds to a low, intermediate or high risk of recurrence. This score can be used, along with other tumor characteristics, to decide on the best treatment for you.
  • MammaPrint Test:
    • This test analyzes the activity of 70 genes found in the tumor cells and uses that information to predict the risk of recurrence (the risk of the cancer coming back after treatment).
    • This test may be used for stage I and II breast cancers that are smaller than 5 centimeters and have no cancer detected in the lymph nodes.
    • The results are reported as either low risk or high risk. This result, along with other characteristics of the tumor, may be used to determine treatment.
  • Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) tests:
    • Higher levels of these biomarkers in the tumor tissue may mean that it is more aggressive (grows faster).
    • These tests may be used in early stage breast cancers that have no cancer detected in the lymph nodes in order to predict prognosis. A very good prognosis may allow a patient to forgo chemotherapy treatment.

Referencias

MammaPrint Test [Internet]. BreastCancer.org; 29 May 2014, cited 17 November 2014. Available at: http://www.breastcancer.org/symptoms/testing/types/mammaprint.

OncoType Dx Test [Internet]. BreastCancer.org; 27 June 2014, cited 17 November 2014. Available at: http://www.breastcancer.org/symptoms/testing/types/oncotype_dx.

Hagemann, I.S. (2016). Molecular Testing in Breast Cancer. Arch Pathol Lab Med, 140, 815-824.

Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., ... & Van Poznak, C. (2016). Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, JCO652289.

Palabras clave

Haga clic en cualquiera de estos términos para más artículos relacionados

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Manténgase informado con las última información de OncoLink!   Suscribirse a los boletines electronico de OncoLink
Ver nuestros archivos de boletines